Eva Fortea Verdejo, an analyst from Wells Fargo, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The associated price target was lowered to $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eva Fortea Verdejo has given her Buy rating due to a combination of factors including iTeos Therapeutics’ continued execution on its pipeline and the potential of its novel targets. The company’s ongoing projects, such as belrestotug and EOS-984, are expected to provide informative data updates in the near future, which could act as catalysts for the stock.
Additionally, the company’s solid cash position, with $624 million expected to sustain operations through 2027, provides a strong financial runway for future developments. Despite the current market challenges, the stock is considered undervalued, and upcoming data from EOS-984 and EOS-215 could offer significant upside potential.